Review
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Mar 27, 2022; 14(3): 482-494
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.482
Hepatitis E in immunocompromised individuals
Konstantinos Damiris, Mohamad Aghaie Meybodi, Mumtaz Niazi, Nikolaos Pyrsopoulos
Konstantinos Damiris, Mohamad Aghaie Meybodi, Department of Medicine, Rutgers - New Jersey Medical School, Newark, NJ 07103, United States
Mumtaz Niazi, Nikolaos Pyrsopoulos, Department of Medicine - Gastroenterology and Hepatology, Rutgers - New Jersey Medical School, Newark, NJ 07103, United States
Author contributions: Damiris K, Aghaie Meybodi M, Niazi M and Pyrsopoulos N equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision/editing; all authors have read and approve the final manuscript.
Conflict-of-interest statement: The authors do not have any conflicts of interest relevant to this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Konstantinos Damiris, DO, MS, Doctor, Department of Medicine, Rutgers - New Jersey Medical School, 150 Bergen Street, Newark, NJ 07103, United States. kd705@njms.rutgers.edu
Received: October 12, 2021
Peer-review started: October 12, 2021
First decision: December 2, 2021
Revised: December 15, 2021
Accepted: February 12, 2022
Article in press: February 12, 2022
Published online: March 27, 2022
Processing time: 162 Days and 23.5 Hours
Core Tip

Core Tip: Hepatitis E Virus is a leading cause of acute icteric hepatitis in developing countries. Despite being self- limiting in most cases, immunocompromised individuals are at a risk of chronic hepatitis, which can be life threatening. Hallmark of treatment includes reduction of immunosuppressive therapies followed by possible need of anti-viral therapy, which has shown to be ineffective.